ICPT Intercept Pharmaceuticals Inc.

Arons & Arons, LLC. Announces Investigation on Behalf of Intercept Pharmaceuticals Inc. Investors

SOUTH ORANGE, N.J.--(BUSINESS WIRE)--

The Law Firm of Arons & Arons, LLC. has initiated an investigation of Intercept Pharmaceuticals Inc. (“Intercept” or the “Company”) (NASDAQ:ICPT) on behalf of the company’s investors for possible violations of federal securities law.

Intercept investors who would like to discuss this investigation and their legal options should contact Arons & Arons, LLC. (Jeffrey S. Arons, Esq.) at (973) 762-0795, (877) 512-7667 or email us at [email protected]. For more information please visit https://www.aronslaw.net/investigations

According to a report issued by Bloomberg, Intercept Pharmaceuticals, Inc. dropped to its lowest price since 2013 today after analysts cut their price targets for the shares. This occurred following reports of additional patient deaths and a warning by the U.S. Food and Drug Administration. On Thursday, the FDA said it has identified 19 deaths of people on the Intercept’s drug, Ocaliva and that the drug may also be associated with liver in injury in some patients with mild diseases who are receiving the correct dose. The company’s stock fell as much as 17 percent on Friday, after dropping 25 percent the day before. Analysts are now calling into question the credibility of Intercept’s management after FDA’s safety announcement raised concerns beyond what was mentioned in a letter the Company sent to doctors the previous week.

If you are an investor in Intercept, or have information pertaining to this investigation, you are encouraged to contact Arons & Arons, LLC. (Jeffrey Arons, Esq.) at (973) 762-0795, (877) 512-7667 or email us at [email protected]. For more information please visit https://www.aronslaw.net/investigations

Arons & Arons, LLC. is a family oriented firm, that provides representation for individuals, including investors who have been victimized by securities fraud. Our attorneys understand the financial and emotional trauma that securities fraud can cause, and we are relentless in our efforts to hold corporate wrongdoers accountable and obtain compensation for our clients. For over 30 years our attorneys have provided personal, accessible, and effective legal representation for our clients. www.aronslaw.net

This press release may be considered Attorney Advertising in some jurisdictions under applicable laws and ethical rules.

EN
22/09/2017

Underlying

ICPTIntercept Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Intercept Pharmaceuticals Inc.

 PRESS RELEASE
Free
ICPT Intercept Pharm...

Intercept Announces New PBC Data Analyses to be Presented at Digestive...

Intercept Announces New PBC Data Analyses to be Presented at Digestive Disease Week® 2024 Conference MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abstracts on primary biliary cholangitis (PBC) will be presented at Digestive Disease Week® (DDW) 2024. The conference will be held from May 18-21 in Washington, D.C. “We are pleased to participate i...

May 9, 2024 1 EN
 PRESS RELEASE
Free
ICPT Intercept Pharm...

Intercept Announces FDA Acceptance of Supplemental New Drug Applicatio...

Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBCPrecedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registriesFDA has assigned a PDUFA target action date of October 15, 2024 MORRISTOWN, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned...

February 29, 2024 1 EN
 PRESS RELEASE
Free
ICPT Intercept Pharm...

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA...

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 2023 Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% reduction from baseline in serum ALP (primary endpoint) Treatment-emergent adverse events were generally balan...

November 13, 2023 1 EN
 PRESS RELEASE
Free
ICPT Intercept Pharm...

Intercept Announces New Findings from Long-term Extension of Landmark ...

Intercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting® 2023 New analysis demonstrates the impact of OCA on achievement of GGT

November 10, 2023 1 EN
 PRESS RELEASE
Free
ICPT Intercept Pharm...

Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.

Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc. BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc. Following the completion of Alfasigma’s successful tender offer to purchase all outstanding shares of common stock of Intercept for USD 19.00 per share, net to the seller thereof in cash, without interest, less any applicable withh...

November 8, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch